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Abstract
Background: We previously reported that the degradation of prohibitin by the SCF
Skp2B ubiquitin ligase results in a defect in
the activity of p53. We also reported that MMTV-Skp2B transgenic mice develop mammary gland tumors that are
characterized by an increased proteolytic cleavage of the insulin-like growth factor binding protein 4 (IGFBP-4), an inhibitor
of IGF signaling. However, whether a link exists between a defect in p53 activity and proteolysis of IGFBP-4 was not
established.
Methods and Results: We analyzed the levels of pregnancy-associated plasma protein A (PAPP-A), the protease of IGFBP-4,
in MMTV-Skp2B transgenic mice and found that PAPP-A levels are elevated. Further, we found a p53 binding site in intron 1
of the PAPP-A gene and that both wild type and mutant p53 bind to this site. However, binding of wild type p53 results in
the transcriptional repression of PAPP-A, while binding of mutant p53 results in the transcriptional activation of PAPP-A.
Since MMTV-Skp2B mice express wild type p53 and yet show elevated levels of PAPP-A, at first, these observations appeared
contradictory. However, further analysis revealed that the defect in p53 activity in Skp2B overexpressing cells does not only
abolish the activity of wild type of p53 but actually mimics that of mutant p53. Our results suggest that in absence of
prohibitin, the half-life of p53 is increased and like mutant p53, the conformation of p53 is denatured.
Conclusions: These observations revealed a novel function of prohibitin as a chaperone of p53. Further, they suggest that
binding of denatured p53 in intron 1 causes an enhancer effect and increases the transcription of PAPP-A. Therefore, these
findings indicate that the defect in p53 function and the increased proteolysis of IGFBP-4, we had observed, represent two
components of the same pathway, which contributes to the oncogenic function of Skp2B.
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Introduction
F-box proteins act as the substrate recognition subunits of
specific ubiquitin ligase complexes. Skp2 is one of the best
characterized F-box proteins and has been implicated in the
degradation of several key regulators of the cell cycle and
checkpoint controls. Like other F-box proteins such as b-TRCP,
Skp2 has been reported to have three alternative splice forms,
Skp2 or Skp2A, Skp2B and Skp2-gamma, although Skp2-gamma
remains uncharacterized. We previously reported that Skp2A and
Skp2B are both overexpressed in breast cancers [1] and that
Skp2B is distinct from Skp2A at several levels; Skp2B localizes to
the cytoplasm rather than the nucleus, further, Skp2B is short lived
compared to Skp2A and does not show a significant effect on
Skp2A substrates [1].
In order to determine whether Skp2B does play a role in breast
cancer, we established transgenic mice overexpressing Skp2B in
the mammary gland under the control of the mouse mammary
tumor virus (MMTV) promoter [2]. We found that MMTV-
Skp2B mice develop a number of phenotypes including acceler-
ation of the invasion of the fat pad during puberty, increased side
branching, pregnancy-like phenotype in virgin females and
mammary tumors [2].
We identified the repressor of the estrogen receptor activity
(REA), as a Skp2B binding protein. Further, since REA
heterozygote mice also display an accelerated fat pad invasion
and accelerated proliferation of the mammary gland during
pregnancy [3], these observations suggested that Skp2B may affect
REA degradation. In agreement with this possibility, we reported
that Skp2B does lead to the ubiquitin-dependent degradation of
REA [2]. However, unlike REA heterozygote mice, MMTV-
Skp2B mice develop mammary gland tumors suggesting that
Skp2B has additional substrates.
We also reported that Skp2B promotes the degradation of
prohibitin [4], a protein associated with multiple functions
including a role as a chaperone for mitochondrial proteins [5,6]
and the activation of p53 [7]. Of particular interest, are the reports
that prohibitin is required for the transcriptional activity of p53
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22456[7,8] since deregulation of p53 is a likely candidate that may
contribute to the mammary gland carcinoma observed in MMTV-
Skp2B mice [2]. Indeed, we also reported that Skp2B overex-
pressing cells show a defect in the transcriptional activity of p53
both in vitro and in vivo [4]. Further analysis of the tumors in
MMTV-Skp2B mice revealed that they are characterized by the
cleavage of insulin-like growth factor binding protein 4 (IGFBP-4)
[2]. IGFBP-4 binds and titrates IGF-II away from the IGF
receptor, therefore inhibiting IGF-II signaling [9,10]. Whether the
increased cleavage of IGFBP-4 [2] and the defect in p53 [4], we
observed in MMTV-Skp2B mammary tumors, are related was
however never addressed.
The defect in p53 activity was associated with an increase in the
baseline levels of p53 protein in Skp2B overexpressing cells raising
the possibility that the turn-over of p53 is reduced in these cells.
The p53 core domain is intrinsically unstable. It is correctly folded
at 37uC, but mild changes in temperatures have been reported to
promote its spontaneous misfolding and denaturation [11].
Similarly, most mutations in p53 share the common property of
reducing the thermostability, and cause p53 denaturation.
Denatured p53 fails to promote the transcription of its ubiquitin
ligase mdm2, resulting in the stabilization of denatured p53 and an
elevation in its basal level. Chaperones such as Hsp90 and 70 assist
the folding of p53 and prevents its denaturation [12]. Whether, a
chaperone of p53 is affected in Skp2B overexpressing cells remain
to be determined.
We therefore initiated this study to investigate the mechanism
leading to the elevated proteolytic cleavage of IGFBP-4 and p53
levels in MMTV-Skp2B transgenic mice. We report two novel
findings; 1) that the expression of the protease of IGFBP-4, PAPP-
A, is repressed by wild type p53 but activated by denatured p53
and 2) that prohibitin acts as a chaperone of p53 such that upon
Skp2B overexpression or treatment with siRNA against prohibitin,
the conformation of p53 becomes denatured and mimics mutant
p53. These results therefore offer a link between the increased
cleavage of IGFBP-4 [2] and the defect in p53 activity [4] we had
previously reported. Further, they suggest that hyperactivation of
IGF-II signaling as a result of IGFBP-4 cleavage is likely to
contribute to the oncogenic function of Skp2B.
Results
Skp2B overexpression and mutant p53 promote the
transcription of PAPP-A
Pregnancy-associated plasma protein-A (PAPP-A) is the prote-
ase required for the cleavage and inactivation of IGFBP-4 [10].
Elevation in PAPP-A represents therefore a likely candidate for the
elevation in IGFBP-4 cleavage we had observed [2]. As the
antibodies against PAPP-A recognized human PAPP-A but not
mouse PAPP-A, we used RT-PCR to determine the levels of
PAPP-A in mice. We found that PAPP-A levels are 4–5 fold higher
in the mammary gland of transgenic mice compare to non-
transgenic mice (Fig. 1A). As a control, the levels of PAPP-A in the
mammary gland during pregnancy in wild type mice were also
determined. We found that PAPP-A levels increase during
pregnancy suggesting that in addition of being secreted into the
circulation from the placenta [13], PAPP-A is also specifically
expressed in the mammary gland during pregnancy (Fig. 1A). To
determine whether elevation in PAPP-A during pregnancy
correlates with a decrease in IGFBP-4 during pregnancy, we next
determine the levels of IGFBP-4 during pregnancy, lactation and
involution of the mammary glands of wild type mice and found
that its levels are low during pregnancy and lactation (Fig. 1B).
These results show for the first time a correlation between PAPP-A
expression and lost of IGFBP-4 in the mammary gland during
pregnancy. Therefore, while PAPP-A expression in the mammary
gland is restricted to pregnancy in wild type mice but is observed
in virgin MMTV-Skp2B transgenic mice, Skp2B must promote
the degradation of a substrate, which results in the abnormal
expression of PAPP-A.
Since we found that Skp2B promotes the degradation of the
repressor of the estrogen receptor activity (REA) [2] and of
prohibitin [4], which leads to the repression of p53 transcriptional
activity, we next tested whether the estrogen receptor (ER) or p53
could be responsible for the activation of PAPP-A transcription.
For this experiment, the p53 and ER negative breast cancer cell
line MDA-MB157 was used. First, MDA-MB157 cells were
transfected with the ER and the level of PAPP-A compared using
RT-PCR since PAPP-A is a secreted protease. We found no
change in the level of PAPP-A following expression of the ER in
these cells (Fig. 1C, D).
We next analyzed the effect of wild type and different mutants
of p53 on the expression of PAPP-A. Upon transfection of wild
type p53, the levels of PAPP-A mRNA were reduced by 2-fold
(Fig. 1E, F). Conversely, transfection of two mutants of p53 (p53–
143 and p53–248) in MDA-MB 157 cells resulted in an elevation
of PAPP-A mRNA by 4–5 folds (Fig. 1G, H). These results
indicate that while wild type p53 represses PAPP-A, mutant p53
gains the ability to activate the transcription of PAPP-A.
To further test the effect of p53 on the expression of PAPP-A,
we analyzed the sequence of the PAPP-A gene for the presence of
a p53-binding site. Since two putative binding sites were identified,
we next tested their ability to bind p53 by ChIP. MDA-MB 157
cells were transfected with wild type and mutant p53 and after
24 hours, cells were fixed with formaldehyde, lysed, sonicated and
ChIP assays were performed. We found that both wild type and
mutant p53 bind to one of the p53 binding site but not the other
(Fig. 1I). These results indicate that binding of mutant p53 to this
site must either recruit activators or prevent binding of repressors
to allow this site to act as an enhancer for the transcription of
PAPP-A. Further, these results indicate that mutant p53 gains the
ability to activate the transcription of PAPP-A independently of
pregnancy.
Elevated levels of PAPP-A mRNA in breast cancer cell
lines expressing mutant p53
To determine whether, a link exists between endogenous p53
and PAPP-A expression, total RNA was extracted from HBL-100
(wild type p53) and HS578T (mutant p53) cells. Total RNA was
subjected to qRT-PCR using human specific primers for the
detection of PAPP-A mRNA levels. We found that the level of
PAPP-A mRNA was 87 fold higher in HS578T cells than HBL-
100 cells (Fig. 2.A, B). Elevated levels of PAPP-A mRNA levels was
also observed in other two breast cancer cell lines harboring
mutant p53 (T47D and MDA-MB 231) (data not shown). To
further explore the potential link between p53 and the expression
of PAPP-A, we then tested the effect of inhibiting wild type p53 by
siRNA on PAPP-A mRNA levels. HBL-100 cells were transfected
with siRNA (30 mM) against p53 and PAPP-A mRNA levels were
determined. We found that inhibition of wild type p53 led to a 3.2
fold increase in PAPP-A levels (Fig. 2.C, D) suggesting that wild
type p53 represses the transcription of PAPP-A. Conversely,
inhibition of mutant p53 siRNA (30 mM) in HS578T cells resulted
in a reduction in PAPP-A mRNA levels (Fig. 2. E, F). This result
supports the notion that mutant p53 activates the transcription of
PAPP-A. Importantly, since PAPP-A is a secreted protein,
elevation in the transcription of PAPP-A by p53 does not result
in an elevation in the intracellular levels of PAPP-A protein. To
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exists between mutant p53 and PAPP-A proteins using breast
carcinoma tissue, which contains the stroma where PAPP-A
resides following its secretion. Microarray duplicate slides were
stained by immunohistochemistry (IHC) using either p53 or anti-
PAPP-A antibody. Detection of p53 by IHC represents a stabilized
form of p53 and therefore is interpreted as representing mutant
p53. In our array, p53 staining was detected in 16% of samples
(Fig. 2G, H), while PAPP-A was observed in 13% (Fig. 2G, H),
further, of the 8 PAPP-A positive tumors, 7 were also positive for
p53 (Fig. 2G, H). Therefore, these results support our vitro
observations in human cell lines that mutant p53 promotes the
transcription of PAPP-A.
Skp2B overexpression promotes the accumulation of
denatured p53
Since wild type p53 represses the expression of PAPP-A but
both mutant p53 and Skp2B overexpression leads to activation of
PAPP-A expression, we next aimed at determining the mechanism
by which wild type p53 in Skp2B overexpressing cells mediates this
effect. The first indication came from the observation that we
consistently observed that the basal level of p53 is higher in Skp2B
overexpressing cells compared to the parental cell line, while the
activity of p53 is reduced [4]. To determine whether this
observation may be due to a difference in the half-life of p53
between the two cell lines, we next performed a cycloheximide
chase. We found that in MCF-7 cells, less than 10% of p53 protein
was detected after 45 minutes (Fig. 3A, B), while in MCF-7Skp2B
cells, 25–30% of p53 protein was detected at 45 minutes (Fig. 3A,
B). This result indicates that the turn-over of p53 is reduced upon
Skp2B overexpression and that p53 may be denatured in these
cells.
While several different mutations exist, most mutations share
the common property of reducing the thermostability, and cause
p53 denaturation. This shared property of denatured p53 is
reflected by the ability of the pAb240 antibody to recognize
multiple different mutants since it detects denatured p53 [14].
Denatured p53 fails to promote the transcription of its ubiquitin
ligase mdm2, resulting in the stabilization of denatured p53 and an
elevation in its basal level. We therefore reasoned that one
potential explanation for our observation is that in absence of
prohibitin, due to Skp2B overexpression, a fraction of total p53
becomes denatured and therefore behaves like mutant p53. To test
this possibility, we took advantage of the pAb240 anti-p53
antibody, which immunoprecipitates only denatured p53 but not
wild-type p53 [14]. For this experiment, T47D breast cancer cells
were used as a positive control since they express mutant p53. We
found that as expected, in T47D cells, p53 levels were elevated
(Fig. 3C, middle panel) due to a defect in mutant p53 turn-over
and that mutant p53 was effectively immunoprecipitated in T47D
cells by the pAb240 antibody (Fig. 3C, top panel). In contrast,
pAb240 failed to immunoprecipitate p53 in MCF-7 cells since p53
is wild-type in these cells. In MCF-7Skp2B cells however, we
found that a small but reproducible fraction of p53 was successfully
immunoprecipitated by pAb240 (Fig. 3C). This observation raises
the possibility that prohibitin prevents p53 denaturation such that
in its absence, a fraction of p53 adopts a non-native conformation
that resembles that of mutant p53, resulting in an increased
stability.
The formation of denatured p53 in absence of prohibitin was
further tested using the analysis of the pattern of cleavage products
following thermolysin digestion. Thermolysin is a protease that has
previously been shown to cleave p53 and generate among other
products, a 27 kDa product containing the DNA binding domain
[15]. Further, the pattern of cleavage products following
thermolysin digestion between wild type p53 and mutants p53
was found to be different and also to vary between mutants [15].
We therefore compare the pattern of p53 cleavage products
following thermolysin digestion in MCF-7 and MCF-7Skp2B cells.
We found that despite the presence of more p53 in MCF-7Skp2B
cells, the level of the 27 kDa product was lower than in MCF-7
cells (Fig. 3D). The ratio p53/27-cleavage product using 200 ng
thermolysin was 3.3 in MCF-7 cells and 15.2 in MCF-7Skp2B cells
indicating a 4.6 fold increase in the p53/27-product ratio.
Collectively, the observations that in MCF-7Skp2B cells; 1) the
turn-over of p53 is extended, 2) pAb240 antibody precipitates p53
and 3) the pattern of p53 cleavage by thermolysin is different, all
strongly argue that upon Skp2B overexpression a fraction of p53
adopts a denatured conformation. To further test the consequence
of such altered conformation on the activity of p53, the levels of
endogenous targets of p53 GADD45 and PUMA were analyzed
following DNA damage using treatment with camptothecin. As we
had reported for p21, a well described transcriptional target of p53
[4], the transcription of both of these endogenous targets were
reduced in Skp2B overexpressing cells compared to the parental
cell line (Fig. 3E, F).
We next tested the viability of MCF-7 or MCF-7Skp2B cells
following treatment with 1 or 2 uM camptothecin. We found that
while the viability of MCF-7 cells after 7 days of treatment with 1
or 2 uM camptothecin was 10% and 1% respectively, the survival
was increased to 20% and 6% in MCF-7kp2B cells (Fig. 3G).
Therefore, these results are consistent with a defect in p53 activity
upon Skp2B overexpression.
Prohibitin affects the folding of p53
Since Skp2B promotes the degradation of prohibitin [4] and
that p53 is denatured in Skp2B overexpressing cells (Fig. 3), we
then ask if prohibitin alone can affect the conformation of p53
using the same approaches. First, we inhibited the expression of
prohibitin using siRNA in MCF-7 cells and determine the levels of
p53 by western blot. We found that inhibition of prohibitin alone
led to an increase in p53 levels (Fig. 4A). This elevation correlated
with a decrease in the turn-over of p53 as determined by
cyclohexmide chase (Fig. 4B). The p53/tubulin ratio at time zero
was set at 1, and the p53/tubulin ratio was determined at each
time point after addition of cycloheximide. This analysis revealed a
Figure 1. p53 regulates PAPP-A levels by binding to the PAPP-A promoter. A) The mammary glands from wild type, pregnant (wild type)
MMTV-Skp2B and tumors were analyzed for the mRNA levels of PAPP-A by quantitative RT-PCR. B) The level of IGFBP-4 in the mammary gland of wild
type mice that are either virgin, pregnant, lactating or involuting was determined by western blot. C) The estrogen receptor null breast cancer cells
MDA-MB-157 were transfected with 3 ug of estrogen receptor plasmid and D) after 24 hours cells were harvested for analyzing the expression of the
estrogen receptor and mRNA levels of PAPP-A by quantitative RT-PCR. E) The p53 null MDA-MB157 cells were transfected with 2 mg of wild type p53
and PAPP-A mRNA levels determined. F) The level of expression of transfected wild type p53 was determined by western blot. G) MDA-MB 157 cells
were transfected with 2 mg of different mutants of p53 (p53–143 and p53–248), 24 hours after, cells were harvested for analysis of PAPP-A mRNA. H)
Western blot showing the expression of mutant p53. Tubulin was used as a loading control. I) p53 binding site on PAPP-A promoter. MDA-MB157
cells transfected with 2 mg of wild type and mutant p53 constructs. After 24 hours of transfection cells were fixed with formaldehyde and collected
for chromatin immunoprecipitation (ChIP) using the p53 (DO-1) antibody. Normal mouse IgG served as a negative control.
doi:10.1371/journal.pone.0022456.g001
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PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e22456Figure 2. p53 regulates PAPP-A levels. A) HBL-100 cells express wild type p53, while HS578T cells express mutant p53. The levels of PAPP-A
mRNA in these cell lines were determined by qRT-PCR. B) Western blot of the levels of p53 in HBL-100 and HS578T cells. C) the expression of p53 was
inhibited in HBL-100 cells using siRNA and the PAPP-A mRNA levels were determined by qRT-PCR. D) the efficiency of siRNA against p53 was
determined by western blot. E) the expression of p53 was inhibited in HS578T cells using siRNA and the PAPP-A mRNA levels were determined by
qRT-PCR. F) the inhibition of p53 by siRNA in HS578T cells was monitored by western blot. G) Duplicate human breast carcinoma tissue microarray
slides (Zymed) were stained by IHC using the DO1 antibody against p53 and the rabbit polyclonal antibody against PAPP-A (Dako). H) The percentage
of tumors positive for p53, PAPP-A or both was determined.
doi:10.1371/journal.pone.0022456.g002
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MCF-7siPHB1 respectively indicating that while 95% of p53 is
degraded by 45 minutes in MCF-7 cells, in MCF7-siPHB1 cells,
20% of p53 remained at this time point (Fig. 4B). Further, the
presence of denatured p53 in MCF-7 cells assessed using
immunoprecipitation with the pAb240 antibody. As we had
observed in Skp2B overexpressing cells (Fig. 3C), while no mutant
p53 could be detected in MCF-7 cells, a fraction of p53 was
detected in MCF-7 cells transfected when prohibitin is inhibited
(Fig. 4C). The effect of inhibition of prohibitin on survival
Figure 3. Skp2B overexpression promotes the accumulation of denatured p53 species. A) Cycloheximide chase in MCF-7 and MCF-7Skp2B
cells was performed for the indicated time and cells were harvested for immunoblotting using anti-p53 antibody. Tubulin was used as a loading
control. B) Quantification of the fraction of p53 remaining in MCF-7 and MCF-7Skp2B cells at the indicated time of cycloheximide treatment. C)
Proteins from MCF-7, MCF-7Skp2B and T47D cells were used for immunoprecipitation of endogenous p53 using the mouse monoclonal pAb240 anti-
p53 antibody, which immunoprecipitates only denatured but not wild-type forms of p53. The immunoblot was then developed using an anti-rabbit
p53 antibody. D) Extracts from MCF-7 and MCF-7Skp2B were digested with increasing concentrations of thermolysin and the resulting cleavage
products detected by immunoblot using the DO1 antibody. The 27kDa product is indicated. E) MCF-7 and MCF-7-Skp2B cells were treated with or
without camptothecin (10 mM) for 4 hours and the levels of GADD45 mRNA levels determined qRT-PCR. The difference between the levels of
GADD45 mRNA following DNA damage between MCF-7 and MCF7-Skp2B cells was statistically significant. The three arrows indicate a p value of less
than 0.0001. F) MCF-7 and MCF-7-Skp2B cells were treated with or without camptothecin (10 mM) for 4 hours and the levels of PUMA mRNA levels
determined qRT-PCR. The difference between the levels of PUMA mRNA following DNA damage between MCF-7 and MCF7-Skp2B cells was
statistically significant. The three arrows indicate a p value of less than 0.0001. G) MCF-7 treated with mock siRNA and MCF-7-Skp2B cells were treated
with 1 or 2 uM camptothecin for 7 days and the percentage of cells that survived determined. The difference between the percentage of cell
surviving following DNA damage between MCF-7 and MCF7-Skp2B cells was statistically significant. The three arrows indicate a p value of less than
0.0001.
doi:10.1371/journal.pone.0022456.g003
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that while 10% and 1% of MCF-7 cells survived after 7 days of
1 uM or 2 uM camptothecin, 17% and 4% survived in MCF-
7Skp2B (Fig. 4D).
Collectively, these results indicate that as we have observed in
Skp2B overexpressing cells, reducing prohibitin by siRNA leads to
the denaturation of p53.
Taken together these results indicate that prohibitin plays an
important role in the conformation of wild type p53 by preventing
its spontaneous misfolding and denaturation.
Discussion
We previously reported an attenuated transcriptional activity of
p53 both in vitro and in vivo [4], as a result of the degradation of
prohibitin by Skp2B. However, this inactivation of p53 was despite
elevated levels of p53 in Skp2B overexpressing cells. We show here
that this elevation in p53 levels is due a slower turn-over of p53 in
these cells. Based on these observations, we propose a model
(Fig. 5) whereby prohibitin acts as a chaperone and protects p53
from adopting a non-native conformation and become denatured.
We postulate that while the majority of p53 adopts a native
conformation (Large arrow Fig. 5), a small fraction may
spontaneously engaged in an incorrect folding pathway. Our data
support the hypothesis that prohibitin assists in preventing
progression through this incorrect folding pathway, which
otherwise lead to misfolding and denatured proteins that are
more stable, such as mutant p53. When Skp2B is overexpressed,
prohibitin is reduced such that the fraction of denatured p53
increases. In Skp2B overexpressing cells (Fig. 5), native p53 is
rapidly degraded by Mdm2 and the denatured p53 fraction
contributes to the elevated level of total p53 observed in these cells.
Also, we found that denatured p53 either due to a mutation of
the loss of prohibitin gains the ability to transcribe PAPP-A (Fig. 5).
Similarly to what has been reported for IGFR-1 [16], our data
indicates that while wild type p53 represses the transcription of
PAPP-A, mutant p53 activates its transcription. This result adds to
the growing list of genes that are regulated by mutant p53
[17,18,19,20,21]. As for the mechanism by which mutant p53
exerts its effect on these genes, so far several different mechanisms
have been reported, while the mechanism remain unclear for
other genes.
Figure 4. Prohibitin affects the conformation of p53. A) MCF-7 cells were transfected with siRNA against prohibitin for 48 hours. The inhibition
of prohibitin expression was confirmed and the levels of p53 determined by immunoblot. B) Cycloheximide chase in MCF-7 and MCF-7 cells treated
with siRNA against prohibitin was performed for the indicated time and cells were harvested for immunoblotting using anti-p53 antibody. Tubulin
was used as a loading control. The quantification of the fraction of p53 remaining in MCF-7 and MCF-7Skp2B cells relative to the amount of p53 at
time 0 is indicated at each time point of cycloheximide treatment. C) Proteins from MCF-7, MCF-7 transfected with siRNA against prohibitin and T47D
cells were used for immunoprecipitation of endogenous p53 using the mouse monoclonal pAb240 anti-p53 antibody, which immunoprecipitates
only mutant but not wild-type forms of p53. The immunoblot was then developed using an anti-rabbit p53 antibody. D) MCF-7 treated with mock
siRNA and MCF-7 cells treated with siRNA against prohibitin were treated with 1 or 2 uM camptothecin for 7 days and the percentage of cells that
survived determined. The difference between the percentage of cell surviving following DNA damage between MCF-7 and MCF7-siPHB cells was
statistically significant. The three arrows indicate a p value of less than 0.0001.
doi:10.1371/journal.pone.0022456.g004
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A gene suggesting that binding of mutant p53 to this site acts as an
enhancer, rather than a direct effect of p53 on the promoter of
PAPP-A. Transcriptional effect of p53 by binding to p53 site in
intronic sequence is not novel as the transcription of GADD45, a
well characterized transcriptional target of p53, is regulated by
binding of p53 to a p53 binding site in intron 3 of the GADD45
gene [22,23,24]. Therefore, our finding expands this mode of
action of p53.
Since PAPP-A inhibits IGFBP-4, our result also expands on the
effect of p53 on the IGF signaling. Wild type p53 is known to
repress the transcription of IGFR1 [16] and to induce the
transcription of IGFBP-3, a negative regulator of IGF-I [25]. Both
of these events contribute to the repression of IGF signaling. Our
data indicates that in addition of these effects, by repressing the
expression of PAPP-A, wild type p53 allows the levels of IGFBP-4
to remain elevated therefore inhibiting IGF-II (Fig. 5). Therefore,
the collective effect of the repression of IGFR-1, activation of
IGFBP-3 and repression of the protease of IGFBP-4 is the
inhibition of the IGF system both at the level of the receptor and
its ligands IGF-I and IGF-II. Conversely, mutant p53 activates the
transcription of IGF1R [16], fails to activate the transcription of
IGFBP-3 and as shown in the present study, activates the
transcription of PAPP-A. This triple hit on the IGF pathway is
likely to contribute to the observation that IGF signaling is
activated in triple negative breast cancer where p53 is frequently
mutated [26,27].
In summary, our results identify a novel axis linking Skp2B-
prohibitin-p53 and the activation of PAPP-A, which results in the
increased cleavage of IGFBP-4 observed in MMTV-Skp2B
transgenic mice. In light of the fact that PAPP-A appears to act
as an oncogene [28,29,30,31] and the potent role of IGF signaling
in cancers [32], this novel axis further supports the oncogenic
function of Skp2B.
Materials and Methods
The authors declare that: All animal work has been conducted
according to Mount Sinai School of Medicine IACUC Animal
ethic committee and was approved by this committee (assurance
number A3111-01).
Cell lines, plasmids and transfections
HS578T and MDA-MB 231, MCF-7 and Skp2B overexpress-
ing (MCF-7-Skp2B) cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum. T47D, HBL-100 and MDA-MB157 cells were grown in
RPMI 1640 supplemented with 10% fetal bovine serum. pCMV-
neo-Bam empty vector and the vectors containing wild type (WT)
p53 and mutant p53 (143, 248) were obtained from Derek Leroith.
All cell lines were obtained commercially from ATCC (USA). All
transfections of plasmid DNA were performed using the Mirus
reagent (TransIT-LT-1, Mirus) according to the manufacturer’s
instructions.
RNA Extraction and Real Time RT-PCR
Total RNA was extracted from cell lines and mammary tissues
using RNeasy Plus Mini Kit (cat. No. 74134) and 100 ng of each
sample was used in real-time RT-PCR reaction using Quantitect
SYBR Green RT-PCR Kit (Cat. No. 204243) following the
Figure 5. Model of the link between Skp2B-prohibitin-p53-PAPP-A–IGFBP-4 and IGF signaling.
doi:10.1371/journal.pone.0022456.g005
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and analyzed as described previously [1] [33]. The following
primers for the quantification of PAPP-A (Human): Forward 59-
GTCAATGTTCCTTCCAGTGC-39 Reverse 59-CTTGTGCT-
TATTCTCTCGGGC-39 and (Mouse): Forward 59-GTTCG-
CCCCTGGTCGGCCATC-39 Reverse 59-CGGCCAGTTCT-
GGGCAGTCG-39 were used in the study along with the beta-
actin primers as loading control.
Transfection of small interfering RNA (siRNAs)
siRNA transfections were performed using Hi-perfect Reagent
(QIAGEN) according to the manufacturer’s protocol. The
following siRNAs were used in the study. siRNA for Luciferase
was used a control: 59-CUUACGCUGAGUACUUCCGATT-39
and 59-UCGAAGGUACUCAGCGUAAGTT-39. For inhibiting
p53: p53 ShortCut siRNA Mix (Cat# N2011S) was purchased
from New England Biolabs and used at a concentration of 30 nM.
Chromatin Immunoprecipitation (ChIp)
ChIP assays were performed using MDA-MB157 cells trans-
fected with wild type p53 and mutant p53 (143) constructs. After
24 hours of transfection cells were used for chromatin immuno-
precipitation, as described previously [34]. Cells were treated with
1% formaldehyde (Sigma) for cross-linking followed by lysis of cells
in RIPA buffer and sonication. The resulted lysates were
incubated with p53 antibody. DNA-p53 complexes were immu-
noprecipitated, using antibody against p53 (DO-1). DNA after
reverse cross-linking and purification (Qia-quick PCR Purification
Kit, Qiagen) was subjected to PCR using the primers (ChIp-qPCR
assay GPH012853 (+)02A (for detecting binding site 1) and ChIP-
qPCR assay GPH012853(+)10A (for detecting binding site 2), (SA
Biosciences) for the amplification of p53 binding sites. PCR
reactions were performed using 5 mL of the DNA from the
immunoprecipitations or the 2 mL of DNA from the input as
template. PCR cycling conditions were as follows: 94uC for 3 min;
then 35 cycles of 94uC for 45 s, 58uC for 45 s, and 72uC for 45 s;
followed by 10 min at 72uC as final extension.
Western blotting and Immunoprecipitation
These methods were performed as described previously [1], and
membranes (Perkin Elmer Life Sciences) were probed with the
following antibodies: rabbit anti-Prohibitin (Biolegend), mouse
prohibitin (Neomarkers) for immunoprecipitation, mouse anti-
FLAG (Sigma), mouse anti-Skp2 (Zymed), mouse anti-tubulin
antibody (Sigma), mouse anti-Myc antibody 9E10 to detect Myc-
ubiquitin, p53 DO-1 (Santa Cruz), anti-IGFBP4 (Upstate), anti-
estrogen receptor (Santa Cruz), anti-PAPP-A (Dako) and pAb240
(generous gift from J. Manfredi). Immunoblots were developed by
ECL (Amersham Pharmacia Biotech).
Luciferase assay
To measure the transcriptional activity of p53, MCF-7 and
MCF-7-Skp2B cells were transfected with the reporter plasmids
pGL3-E1bTATA or p21 promoter-pGL2. Cells were also
transfected with a plasmid constitutively expressing the Renilla
luciferase. After 24 hours, luciferase activity was measured using a
dual luciferase reporter assay system (Promega) according to the
manufacturer’s instructions. To calculate the relative luciferase
activities, the ratio of the respective firefly and Renilla luciferase
activities were determined. Luciferase assays were quantitated
using a TD-20/20 Luminometer.
Proteolytic digests of p53
Thermolysin (Sigma) digests were carried out on 20 mg of total
protein extracts from either MCF-7 or MCF-7Skpk2B cells at
20 C in 50 ml reaction buffer containing 25 mM Tris pH 8.5,
10 mM MgCl2 and 1 mM DTT and 200 or 400 ng thermolysin
for 20 minutes as described previously [35].
Immunohistochemistry. For immunostaining of paraffin
sections, a mouse monoclonal antibody against human p53 (Santa
Cruz, DO-1) was used at a concentration of 1:100 and the rabbit
polyclonal antibody against PAPP-A (Dakocytomation) was used
at a dilution of 1:50. Immunohistochemical staining of PAPP-A
and p53 were performed on archival formalin-fixed tissue sections
(3 to 5 um), which were dewaxed and rehydrated in water.
Antigen retrieval was achieved in a pressure cooker for 2 minutes
in 10 mM sodium citrate pH 6.0. Endogenous peroxidase activity
was blocked with 3% (v/v) hydrogen peroxide for 10 minutes. All
buffer washes between antibody incubations were with 50 mM
Tris-HCl pH 7.6. The primary antibodies were incubated for
1:30 hour at room temperature and detected with the LSAB+ kit
peroxidase (DAKO, K0690), with the link biotinylated anti-rabbit
or mouse IgG for 1 hour and streptavidin peroxidase for
15 minutes. Slides were developed with AEC (3-amino-9-ethyl-
carbazole) chromogen (DAKO) for 15 minutes. Sections were
then counterstained in haematoxylin and mounted with DPX.
Scoring assessment. Demonstration of p53 and PAPP-A
staining was assessed according to both the extent and the intensity
of the staining. The extent ranges on a scale from 0 to 5 where a
score of 0 indicated less than 10% of the cells were stained, 1 for
11–25%, 2 for 26–50%, 3 for 51–75%, 4 for 76–90% and 5 for
more then 90% of the cells. The intensity was scored on a scale
from 0 to 3 where 0 is negative and 3 is the strongest intensity of
staining. The score for extent and intensity was then added and
considered weak if the total score was between 1–3, moderate
between 4–6 and strong when above 7. In this study, cancer
sections were considered positive for p53 and PAPP-a staining if
they scored either moderate or strong.
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